Brokers Offer Predictions for KalVista Pharmaceuticals, Inc.’s FY2026 Earnings (NASDAQ:KALV)

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Leerink Partnrs issued their FY2026 earnings per share (EPS) estimates for KalVista Pharmaceuticals in a research note issued on Thursday, September 5th. Leerink Partnrs analyst J. Schwartz anticipates that the specialty pharmaceutical company will earn ($2.17) per share for the year. The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.57) per share.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) EPS for the quarter, topping the consensus estimate of ($0.91) by $0.04.

A number of other brokerages also recently issued reports on KALV. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a research report on Friday. Cantor Fitzgerald upgraded shares of KalVista Pharmaceuticals to a “strong-buy” rating in a research note on Monday, August 26th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday.

KalVista Pharmaceuticals Price Performance

KALV opened at $12.34 on Monday. The firm has a market capitalization of $520.60 million, a PE ratio of -3.63 and a beta of 0.89. The business’s 50-day moving average is $13.17 and its two-hundred day moving average is $12.40. KalVista Pharmaceuticals has a 1 year low of $7.21 and a 1 year high of $16.88.

Insiders Place Their Bets

In other news, CEO Benjamin L. Palleiko sold 14,215 shares of the company’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $12.01, for a total transaction of $170,722.15. Following the transaction, the chief executive officer now owns 242,527 shares in the company, valued at $2,912,749.27. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, CEO Benjamin L. Palleiko sold 14,215 shares of KalVista Pharmaceuticals stock in a transaction on Monday, August 19th. The shares were sold at an average price of $12.01, for a total transaction of $170,722.15. Following the completion of the sale, the chief executive officer now directly owns 242,527 shares in the company, valued at $2,912,749.27. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Paul K. Audhya sold 2,135 shares of the company’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $12.40, for a total value of $26,474.00. Following the completion of the transaction, the insider now directly owns 83,745 shares in the company, valued at $1,038,438. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 23,452 shares of company stock valued at $282,491. 12.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Campbell & CO Investment Adviser LLC acquired a new position in KalVista Pharmaceuticals in the 4th quarter worth approximately $507,000. Frazier Life Sciences Management L.P. increased its stake in shares of KalVista Pharmaceuticals by 11.8% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 3,622,294 shares of the specialty pharmaceutical company’s stock worth $44,373,000 after acquiring an additional 383,435 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in shares of KalVista Pharmaceuticals by 101.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 8,024 shares of the specialty pharmaceutical company’s stock worth $95,000 after purchasing an additional 4,043 shares during the last quarter. BNP Paribas Financial Markets lifted its position in KalVista Pharmaceuticals by 94.5% during the first quarter. BNP Paribas Financial Markets now owns 18,013 shares of the specialty pharmaceutical company’s stock valued at $214,000 after purchasing an additional 8,750 shares during the period. Finally, ClariVest Asset Management LLC purchased a new stake in KalVista Pharmaceuticals in the first quarter valued at $659,000.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.